USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression

被引:9
|
作者
Li, Bing [1 ]
Wang, Bin [2 ]
机构
[1] Tianjin Huanhu Hosp, Dept Neurosurg, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 JiZhao Rd, Tianjin 300350, Peoples R China
[2] Tianjin Huanhu Hosp, Dept Intervent Radiol, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, Tianjin, Peoples R China
关键词
Glioma; immune escape; PD-L1; USP7; CANCER; UBIQUITINATION; INHIBITION; PROGNOSIS;
D O I
10.1080/08820139.2022.2083972
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Glioma is the most common primary intracranial tumor. This study investigated the mechanism of ubiquitin-specific processing protease 7 (USP7) on the immune escape of glioma cells via the regulation of programmed cell death ligand-1 (PD-L1). Methods USP7 and PD-L1 expressions in glioma and normal brain tissues were detected using quantitative reverse transcriptase polymerase chain reaction and Western blot. The glioma cells U-251 MG were transfected with si-USP7 and pcDNA3.1-PD-L1, or treated with anti-PD-L1, after which the cell viability, colony-forming ability, and apoptosis rate were evaluated using cell counting kit-8, colony formation, and TdT-mediated dUTP nick-end labeling assays. Then, CD8+ T cells were purified, extracted, then co-cultured with U-251 MG cells. CD8+ T cell proliferation and the concentrations of interferon (IFN-gamma), tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta, interleukin (IL)-1 beta, and IL-10 were verified using carboxyfluorescein succinimidyl amino ester proliferation assay and enzyme-linked immunosorbent assay. Afterwards, the interaction between USP7 and PD-L1 and the ubiquitination level of PD-L1 were also assessed. Results USP7 was highly-expressed and PD-L1 mRNA levels did not change, while PD-L1 protein levels were up-regulated in the glioma cells. Silencing USP7 in U-251 MG cells limited the growth of the glioma cells, promoted glioma cell apoptosis, and facilitated the proliferation of CD8+ T cells, thus inhibiting immune escape. USP7 stabilized PD-L1 expression through deubiquitination. PD-L1 overexpression reversed the inhibitory effect of silencing USP7 on the immune escape of glioma cells. Conclusion USP7 stabilized PD-L1 through deubiquitination and accelerated the immune escape of glioma cells.
引用
收藏
页码:1921 / 1937
页数:17
相关论文
共 50 条
  • [41] Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression
    Yang, Fan
    Lin, Ling
    Li, Xiaohua
    Wen, Ronglan
    Zhang, Xin
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (11) : 1959 - 1969
  • [42] The prognostic value of PD-L1/PD-1 expression and PD-L1 gene copy number on/in tumor and immune cells in triple negative breast cancer
    Seitz, S.
    Brockhoff, G.
    Weber, F.
    Klinkhammer-Schalke, M.
    Zeman, F.
    Ugocsai, P.
    Ortmann, O.
    Wege, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
  • [43] APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1
    Liu, Ying
    Li, Nan
    Guo, Yilin
    Zhou, Qing
    Yang, Yuqin
    Lu, Jiaxue
    Tian, Ziying
    Zhou, Jieyu
    Yan, Shiqi
    Li, Xiayu
    Shi, Lei
    Jiang, Su
    Ge, Junshang
    Feng, Ranran
    Huang, Donghai
    Zeng, Zhaoyang
    Fan, Songqing
    Xiong, Wei
    Li, Guiyuan
    Zhang, Wenling
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [44] PPARγ inhibited tumor immune escape by inducing PD-L1 autophagic degradation
    Gou, Qian
    Che, Suning
    Chen, Mingjun
    Chen, Huiqing
    Shi, Juanjuan
    Hou, Yongzhong
    CANCER SCIENCE, 2023, 114 (07) : 2871 - 2881
  • [45] The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia.
    Ding, Xingchen
    Yu, Jinming
    Hu, Man
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
    Garcia-Diaz, Angel
    Shin, Daniel Sanghoon
    Moreno, Blanca Homet
    Saco, Justin
    Escuin-Ordinas, Helena
    Rodriguez, Gabriel Abril
    Zaretsky, Jesse M.
    Sun, Lu
    Hugo, Willy
    Wang, Xiaoyan
    Parisi, Giulia
    Saus, Cristina Puig
    Torrejon, Davis Y.
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Hu-Lieskovan, Siwen
    Damoiseaux, Robert
    Lo, Roger S.
    Ribas, Antoni
    CELL REPORTS, 2017, 19 (06): : 1189 - 1201
  • [47] Does PD-L1 Positivity in Inflammatory Cells Correlate with PD-L1 Expression in Tumor Cells in Colorectal Adenocarcinoma?
    Broadwater, D. R.
    Williams, G.
    Messersmith, L.
    Brady, R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S157 - S157
  • [48] PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing
    Akhmetzyanova, Ilseyar
    Drabczyk, Malgorzata
    Neff, C. Preston
    Gibbert, Kathrin
    Dietze, Kirsten K.
    Werner, Tanja
    Liu, Jia
    Chen, Lieping
    Lang, Karl S.
    Palmer, Brent E.
    Dittmer, Ulf
    Zelinskyy, Gennadiy
    PLOS PATHOGENS, 2015, 11 (10)
  • [49] Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells
    Xu, Wenjie
    Liu, Shuyi
    Zhang, Genshan
    Liu, Jin
    Cao, Gang
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (05) : 455 - 464
  • [50] Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
    Knopf, Philipp
    Stowbur, Dimitri
    Hoffmann, Sabrina H. L.
    Hermann, Natalie
    Maurer, Andreas
    Bucher, Valentina
    Poxleitner, Marilena
    Tako, Bredi
    Sonanini, Dominik
    Krishnamachary, Balaji
    Sinharay, Sanhita
    Fehrenbacher, Birgit
    Gonzalez-Menendez, Irene
    Reckmann, Felix
    Bomze, David
    Flatz, Lukas
    Kramer, Daniela
    Schaller, Martin
    Forchhammer, Stephan
    Bhujwalla, Zaver M.
    Quintanilla-Martinez, Leticia
    Schulze-Osthoff, Klaus
    Pagel, Mark D.
    Fransen, Marieke F.
    Roecken, Martin
    Martins, Andre F.
    Pichler, Bernd J.
    Ghoreschi, Kamran
    Kneilling, Manfred
    MOLECULAR CANCER, 2023, 22 (01)